Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.
Age ≥ 18 years
Primary ED complaints of acute or episodic nausea, vomiting, and/or abdominal pain
Self reported frequent cannabis use
History of recurrent, cyclical episodes of severe nausea and vomiting
Patients with imaging or lab findings suggestive of an alternative etiology that would explain their symptoms
Already on dopamine agonist/antagonist therapy for another condition
Parkinson's disease
Lewy body dementia
Single group
Haloperidol
DrugThis intervention involves providing patients an outpatient prescription for as needed haloperidol to attempt to control symptoms of cannabinoid hyperemesis and to attempt to prevent return to the emergency department for that reason.
Rate of return to the emergency department
The investigators plan to measure the percentage of people who return to the emergency department for recurrence of symptoms attributable to cannabinoid hyperemesis syndrome
Improvement in symptoms
The investigators plan to report patient reported change in symptoms attributable to cannabinoid hyperemesis syndrome. The subjects will report change in their symptoms via a 5 point likert scale with 1 being no change in symptoms at all and 5 being complete resolution of symptoms.
Medication side effects
The investigators plan to report the rate of patient reported side effects that are considered attributable to cannabinoid hyperemesis syndrome
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
